根据世界卫生组织（世卫组织）与MSD for Mothers和辉凌制药合作开展的一项研究，一种用来预防产后出血的新配方药物可挽救低收入和中低收入国家成千上万名妇女的生命。
A new formulation of a drug to prevent excessive bleeding following childbirth could save thousands of women’s lives in low- and lower-middle-income countries, according to a study led by WHO in collaboration with MSD for Mothers and Ferring Pharmaceuticals.
11873
世卫组织目前建议将催产素作为预防产后出血的首选药物。
Currently, WHO recommends oxytocin as the first-choice drug for preventingexcessive bleeding after childbirth.
Oxytocin, however, must be stored and transported at 2–8 degrees Celsius, which is hard to do, in many countries, depriving many women of access to this lifesaving drug.
11875
而即便她们能够获得，因高温作用缘故，药物效果可能遭到削弱。
When they can obtain it, the drug may be less effective because of heat exposure.
The study, published today in the New England Journal of Medicine, has shown an alternative drug – heat-stable carbetocin – to be as safe and effective as oxytocin in preventing postpartum haemorrhage.
This new formulation of carbetocin does not require refrigeration and retains its efficacy for at least3 yearsstored at 30 degrees celsius and 75% relative humidity.
“This is a truly encouraging new development that can revolutionize our ability to keep mothers and babies alive,” says Dr Tedros Adhanom Ghebreyesus, Director-General of WHO.
11879
每年约有7万名妇女因产后出血死亡，进而会增加婴儿在出生后一个月内死亡的风险。
Approximately 70 000 women die every year because of post-partum haemorrhage – increasing the risk that their babies also die within one month.
The clinical trial, the largest of its kind, studied close to 30 000 women who gave birth vaginally in 10 countries: Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the United Kingdom.